SCHEMBL7180432

SCHEMBL7180432

COc1ccc(C(=O)P(=O)(C(=O)c2c(Cl)cccc2OC)c2ccccc2)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 4/20 0.50
NPC1 O15118 4/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
RAB9A P51151 3/20 0.46
MAPT P10636 4/20 0.46
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 2/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
TOP1 P11387 1/20 0.42
LMNA P02545 1/20 0.41
ITGB1 P05556 1/20 0.41
ITGA4 P13612 1/20 0.41
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183303 0.95 ABCG2 (0.52) ABCG2NPC1MEN1KMT2ARAB9A
SCHEMBL7177176 0.92 NPC1 (0.51) ABCG2NPC1MEN1KMT2ARAB9A
SCHEMBL7180885 0.91 ABCG2 (0.48) ABCG2NPC1MEN1KMT2ARAB9A
SCHEMBL7175981 0.89 ABCG2 (0.44) ABCG2NPC1KMT2ARAB9AMAPT
SCHEMBL28604964 0.87 NPC1 (0.58) ABCG2NPC1MEN1KMT2ARAB9A
SCHEMBL7187909 0.86 NPC1 (0.52) ABCG2NPC1MEN1KMT2ARAB9A
SCHEMBL7181642 0.86 CA12 (0.47) MAPTALDH1A1HTTGAAITGB1
SCHEMBL7178231 0.86 CA12 (0.47) MAPTALDH1A1HTTGAAITGB1
SCHEMBL7188247 0.85 MAPT (0.51) ABCG2NPC1MEN1KMT2ARAB9A
SCHEMBL7175458 0.83 ABCG2 (0.46) ABCG2NPC1MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1200943-C Organometallic acyl-aryl phosphine CIBA SC HOLDING AG (CH) 2005-05-11 CN disclosed
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed
CN-1308081-A Organometallic acyl-aryl phosphine CIBA SC HOLDING AG (CH) 2001-08-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ABCG2 3732/4885NPC1 772/4885MEN1 2312/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ABCG2 4323/4885NPC1 872/4885MEN1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.